reports
Build A Bear Workshop Inc: 2 directors
Two Directors at Build A Bear Workshop Inc sold 40,000 shares at between 73.252USD and 73.252USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
- Wedbush Research
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Revolution Medicines Shares New Clinical Results Supporting Initiation...
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for daraxonrasib monotherapy and daraxonrasib plus chemotherapy in first line metastatic pancreatic ductal adenocarcinoma support planned initiation of three-arm Phase 3 trial in Q4 202...
PureCycle Completes Additional BOPP Film Trials With Brückner
PureCycle Completes Additional BOPP Film Trials With Brückner PCR-Based Film Suitable for Food Packaging and Labels ORLANDO, Fla., Sept. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT) announced today the successful completion of larger-scale trials with PureFive™ resin in biaxially oriented polypropylene (BOPP) film. 16,000 meters of nearly 1-meter-wide BOPP film, at various thicknesses, was produced over two days. The latest trials were conducted in August by Germany-based Brückner Maschinenbau GmbH, the world’s leading supplier of production lines for manufacturing a wide range of stre...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Mos...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited tre...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global In...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. An on-demand webc...
PureCycle Receives Association of Plastic Recyclers’ PCR Certification
PureCycle Receives Association of Plastic Recyclers’ PCR Certification ORLANDO, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT) announced today that it has successfully completed a third-party audit and achieved the Association of Plastic Recyclers’ (APR) Post-Consumer Resin (PCR) Certification for the Company’s primary grade of PureFive™ resin, HPP15-100. This certification provides verification that it was manufactured from post-consumer sources. The HPP15-100 grade of PureFive™ resin is the primary material produced at the Company’s Ironton Facility. It is also the base recycle...
Beyond Air Signs New International LungFit PH® Distribution Agreements...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient lives, today announced the expansion of its global LungFit® PH distribution network. The Company has recentl...
Cleveland Browns Achieve True Circularity with PureFive™ Resin in Souv...
Cleveland Browns Achieve True Circularity with PureFive™ Resin in Souvenir Cups ORLANDO, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT) announced today the Cleveland Browns, a professional American football team, will use 100% PureFive™ resin in their 2025 line of player souvenir cups. As PureZero™ partners, the Cleveland Browns and PureCycle have worked together to improve recycling at Huntington Bank Field by delivering polypropylene plastic waste generated at games to PureCycle’s Ironton, Ohio recycling facility. Now the companies are taking it one step further by introducing t...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
UNH UNITEDHEALTH GROUP INCORPORATED
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
ROFIN SINAR TECH
RRGB RED ROBIN GOURMET BURGERS INC.
PBYI PUMA BIOTECHNOLOGY INC.
KE KIMBALL ELECTRONICS
GAIA GAIA INC CL A
UEC UNIMIT ENGINEERING
FI FRANK'S INTERNATIONAL NV
FSLR FIRST SOLAR INC.
DK DELEK US HOLDINGS INC
NEON NEONODE INC.
LYFT LYFT
ZETA ZETA GLOBAL HLDGS CORP
ARHS ARHAUS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
ESEA EUROSEAS LTD
VERB VERB TECHNOLOGY COMPANY INC.
MPLN MULTIPLAN CORPORATION
BKTI BK TECHNOLOGIES CORP
RIGL RIGEL PHARMACEUTICALS INC.
CSIOX CATALYST PERINI STRATEGIC INCOM ORD
SCLX SCILEX HOLDING COMPANY
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Pr...
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network Reaffirm revenue guidance of $12-$16 million for the full fiscal year 2026 Conference call at 4:30 p.m. ET today, August 12th GARDEN CITY, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAI...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
PureCycle Technologies Second Quarter 2025 Corporate Update
PureCycle Technologies Second Quarter 2025 Corporate Update ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today a corporate update for the second quarter ending June 30, 2025. Management Commentary PureCycle CEO Dustin Olson commented, “We have begun to implement our growth plans following our successful $300 million capital raise that was executed in June. Our first expansion steps will be with facilities in Thailand and Belgium. Future facilities, beyond the initial lines in Thailand and Belgium, are ...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
BKNG BOOKING HOLDINGS INC.
RCUS ARCUS BIOSCIENCES
UBER UBER TECHNOLOGIES INC.
DT DYNATRACE INC.
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
STX SEAGATE TECHNOLOGY HLDGS PLC
APP APPLOVIN CORP
YOU CLEAR SECURE INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Revolution Medicines Reports Second Quarter 2025 Financial Results and...
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Ti...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
CVCO CAVCO INDUSTRIES INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
HEAR TURTLE BEACH CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
SMCI SUPER MICRO COMPUTER
RVMD INC.
CRSR REVOLUTION MEDICINES
PRAX CORSAIR GAMING
TVTX PRAXIS PRECISION MEDICINES
PLTK TRAVERE THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
DAWN NUVATION BIO INC (A)
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
GFS INC
SKLZ SEAGATE TECHNOLOGY HLDGS PLC
CBIO GLOBALFOUNDRIES INC
SKILLZ INC
CRESCENT BIOPHARMA INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
Revolution Medicines to Report Financial Results for Second Quarter 20...
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.